Literature DB >> 11097231

K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.

R J Slebos1, J A Hoppin, P E Tolbert, E A Holly, J W Brock, R H Zhang, P M Bracci, J Foley, P Stockton, L M McGregor, G P Flake, J A Taylor.   

Abstract

Pancreatic cancer is a highly fatal cancer with few identified risk factors. Increased risk of pancreatic cancer in tobacco smokers and among diabetic patients is well established, and some reports have suggested associations with coffee consumption and occupational exposure to organochlorines. At present, there is little information regarding the possible association of these risk factors with the known genetic alterations found in pancreatic cancers, such as activation of the K-ras oncogene and inactivation of the p53 tumor suppressor gene. Knowledge of such relationships may help to understand the molecular pathways of pancreatic tumorigenesis. We investigated the association between these molecular defects and risk factors for pancreatic cancer in 61 newly diagnosed patients identified through an ongoing study of pancreatic cancer in the San Francisco Bay Area. Interview information was obtained regarding environmental exposures, medical history, and demographic factors. Serum levels of dichlorodiphenyltrichloroethylene (DDE) and polychlorinated biphenyls were available on a subset of 24 patients. Tumor blocks were located from local hospitals and used for K-ras mutational analysis at codon 12 and for p53 protein immunohistochemistry. The molecular analyses were facilitated through the use of laser capture microdissection, which provides a reliable method to obtain almost pure populations of tumor cells. Mutations in K-ras codon 12 were found in 46 (75%) of 61 pancreatic cancers. A prior diagnosis of diabetes was significantly associated with K-ras negative tumors (P = 0.002, Fisher's exact test). The absence of this mutation was also associated with increased serum levels of DDE, although this association was not statistically significant (P = 0.16, Wilcoxon's test). There was no difference in polychlorinated biphenyl levels between the K-ras wild-type and mutant groups. Immunohistochemical staining for p53 protein did not differ by patient characteristics or clinical history, but significant associations were found with poor glandular differentiation (P = 0.002, chi2 trend test), severe nuclear atypia (P = 0.0007, chi2 trend test), and high tumor grade (P = 0.004, chi2 trend test). Our results are suggestive of the presence of K-ras codon 12 mutation-independent tumorigenesis pathways in patients with prior diabetes and possibly in patients with higher serum levels of DDE. Our results also support a role for the p53 tumor suppressor protein in the maintenance of genomic integrity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11097231

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  31 in total

1.  Gene expression profiles of microdissected pancreatic ductal adenocarcinoma.

Authors:  Robert Grützmann; Melanie Foerder; Ingo Alldinger; Eike Staub; Thomas Brümmendorf; Stefan Röpcke; Xinzhong Li; Glen Kristiansen; Ralf Jesenofsky; Ralf Jesnowski; Bence Sipos; Matthias Löhr; Jutta Lüttges; Detlef Ockert; Günter Klöppel; Hans Detlev Saeger; Christian Pilarsky
Journal:  Virchows Arch       Date:  2003-08-27       Impact factor: 4.064

Review 2.  Pancreatic cancer, treatment options, and GI-4000.

Authors:  Marion L Hartley; Najeebah A Bade; Petra A Prins; Leonel Ampie; John L Marshall
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Detecting pathway-based gene-gene and gene-environment interactions in pancreatic cancer.

Authors:  Eric J Duell; Paige M Bracci; Jason H Moore; Robert D Burk; Karl T Kelsey; Elizabeth A Holly
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06       Impact factor: 4.254

4.  Risk of pancreatic cancer by alcohol dose, duration, and pattern of consumption, including binge drinking: a population-based study.

Authors:  Samir Gupta; Furong Wang; Elizabeth A Holly; Paige M Bracci
Journal:  Cancer Causes Control       Date:  2010-03-27       Impact factor: 2.506

5.  Adjusting serum concentrations of organochlorine compounds by lipids and symptoms: a causal framework for the association with K-ras mutations in pancreatic cancer.

Authors:  Tomàs López; José A Pumarega; Anna Z Pollack; Duk-Hee Lee; Lorenzo Richiardi; David R Jacobs; Enrique F Schisterman; Miquel Porta
Journal:  Chemosphere       Date:  2014-05-20       Impact factor: 7.086

Review 6.  Pancreatic cancer, treatment options, and GI-4000.

Authors:  Marion L Hartley; Najeebah A Bade; Petra A Prins; Leonel Ampie; John L Marshall
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Food and nutrient intakes and K-ras mutations in exocrine pancreatic cancer.

Authors:  Eva Morales; Miquel Porta; Jesús Vioque; Tomás López; Michelle A Mendez; José Pumarega; Núria Malats; Marta Crous-Bou; Joy Ngo; Juli Rifà; Alfredo Carrato; Luisa Guarner; Josep M Corominas; Francisco X Real
Journal:  J Epidemiol Community Health       Date:  2007-07       Impact factor: 3.710

8.  Availability and accuracy of medical record information on language usage of cancer patients from a multi-ethnic population.

Authors:  Laura A McClure; Sally L Glaser; Sarah J Shema; Laura Allen; Charles Quesenberry; Esther M John; Scarlett L Gomez
Journal:  J Immigr Minor Health       Date:  2010-08

9.  Sweets, sweetened beverages, and risk of pancreatic cancer in a large population-based case-control study.

Authors:  June M Chan; Furong Wang; Elizabeth A Holly
Journal:  Cancer Causes Control       Date:  2009-03-11       Impact factor: 2.506

10.  Pancreatitis and pancreatic cancer in two large pooled case-control studies.

Authors:  Paige M Bracci; Furong Wang; Manal M Hassan; Samir Gupta; Donghui Li; Elizabeth A Holly
Journal:  Cancer Causes Control       Date:  2009-11       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.